Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma

被引：10
作者：
Wu, Lan [1 ,2 ,3 ]
Wang, Chong [4 ,5 ,6 ,7 ]
Zhang, Dapeng [1 ,2 ,3 ]
Zhang, Xunming [1 ,2 ,3 ]
Qian, Weizhu [1 ,2 ,3 ,4 ,5 ]
Zhao, Lei [1 ,2 ,3 ]
Wang, Hao [1 ,2 ,3 ,4 ,5 ]
Li, Bohua [1 ,2 ,3 ,4 ,5 ]
Guo, Yajun [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China
[2] Second Mil Med Univ, Gen Hosp Canc Ctr 301, Shanghai 200433, Peoples R China
[3] Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China
[4] Natl Engn Res Ctr Antibody Med, Shanghai 201203, Peoples R China
[5] Shanghai Key Lab Cell Engn & Antibody, Shanghai 201203, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China
[7] Shanghai Jiao Tong Univ, Sch Pharm, Ctr Antibody Med, Minist Educ, Shanghai 200025, Peoples R China
来源：
CANCER LETTERS | 2010年 / 292卷 / 02期
基金：
中国国家自然科学基金;
关键词：
CD20; Humanized antibody; Complement-dependent cytotoxicity; B-cell lymphoma; NON-HODGKINS-LYMPHOMA; MONOCLONAL-ANTIBODIES; RITUXIMAB TREATMENT; IN-VIVO; MECHANISMS; LYMPHOCYTES; FRAMEWORK; RESIDUES; THERAPY; CD20;
D O I：
10.1016/j.canlet.2009.12.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite the effectiveness of the anti-CD20 chimeric antibody (mAb), rituximab, in treating B-cell lymphomas, its efficacy remains variable and often modest. In this study, a humanized anti-CD20 antibody, hu8E4, was generated by complementary-determining region grafting method Hu8E4 was as effective as rituximab in mediating antibody-dependent cellular cytotoxicity and inducing apoptosis in B-lymphoma cells, but it exhibited much more potent complement-dependent cytotoxicity than rituximab Immunotherapeutic studies showed that hu8E4 was significantly more effective than rituximab in prolonging the survival of severe combined immunodeficient mice bearing human B-cell lymphomas, suggesting that It might be a promising therapeutic agent for B-cell lymphomas. (C) 2009 Elsevier Ireland Ltd. All rights reserved
引用
收藏
页码：208 / 214
页数：7
相关论文
共 23 条
[1]   Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].
Anderson, DR ;
GrilloLopez, A ;
Varns, C ;
Chambers, KS ;
Hanna, N .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708
[2]   From the bench to the bedside: ways to improve rituximab efficacy [J].
Cartron, G ;
Watier, H ;
Golay, J ;
Solal-Celigny, P .
BLOOD, 2004, 104 (09) :2635-2642
[3]   Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents [J].
Cragg, MS ;
Glennie, MJ .
BLOOD, 2004, 103 (07) :2738-2743
[4]   Complement activation determines the therapeutic activity of rituximab in vivo [J].
Di Gaetano, N ;
Cittera, E ;
Nota, R ;
Vecchi, A ;
Grieco, V ;
Scanziani, E ;
Botto, M ;
Introna, M ;
Golay, J .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1581-1587
[5]  
Eisenbeis CF, 2003, CLIN CANCER RES, V9, P5810
[6]   Mechanisms of killing by anti-CD20 monoclonal antibodies [J].
Glennie, Martin J. ;
French, Ruth R. ;
Cragg, Mark S. ;
Taylor, Ronald P. .
MOLECULAR IMMUNOLOGY, 2007, 44 (16) :3823-3837
[7]  
Kabat E.A., 1987, SEQUENCES PROTEINS I
[8]   HUMANIZATION OF A MOUSE MONOCLONAL-ANTIBODY BY CDR-GRAFTING - THE IMPORTANCE OF FRAMEWORK RESIDUES ON LOOP CONFORMATION [J].
KETTLEBOROUGH, CA ;
SALDANHA, J ;
HEATH, VJ ;
MORRISON, CJ ;
BENDIG, MM .
PROTEIN ENGINEERING, 1991, 4 (07) :773-783
[9]   Generation and production of engineered antibodies [J].
Kipriyanov, SM ;
Le Gall, F .
MOLECULAR BIOTECHNOLOGY, 2004, 26 (01) :39-60
[10]   DERIVATION OF SPECIFIC ANTIBODY-PRODUCING TISSUE-CULTURE AND TUMOR LINES BY CELL-FUSION [J].
KOHLER, G ;
MILSTEIN, C .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1976, 6 (07) :511-519
123